Dr. Usmani on Combining Daratumumab for Multiple Myeloma

Saad Z. Usmani, MD
Published Online: Thursday, Apr 20, 2017



Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses combining daratumumab (Darzalex) for patients with multiple myeloma.

Depending on the therapy that patients have received for their first-line of treatment, daratumumab may have the ability to be paired with other agents, explains Usmani.

A concern that physicians have is long-term effects of daratumumab on the immune system. As of now, there is no clinically significant concerns but it is something we will continue to watch, states Usmani.
 


Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses combining daratumumab (Darzalex) for patients with multiple myeloma.

Depending on the therapy that patients have received for their first-line of treatment, daratumumab may have the ability to be paired with other agents, explains Usmani.

A concern that physicians have is long-term effects of daratumumab on the immune system. As of now, there is no clinically significant concerns but it is something we will continue to watch, states Usmani.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 12th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 29, 20172.0
Cancer Summaries and Commentaries™: 2016 Conference Coverage: Advances in the Treatment of Genitourinary CancersApr 29, 20172.5
Publication Bottom Border
Border Publication